347 related articles for article (PubMed ID: 31295358)
1. Cost-effectiveness analysis of empagliflozin treatment in people with Type 2 diabetes and established cardiovascular disease in the EMPA-REG OUTCOME trial.
Kansal A; Reifsnider OS; Proskorovsky I; Zheng Y; Pfarr E; George JT; Kandaswamy P; Ruffolo A
Diabet Med; 2019 Nov; 36(11):1494-1502. PubMed ID: 31295358
[TBL] [Abstract][Full Text] [Related]
2. Cost-Effectiveness of Empagliflozin for the Treatment of Patients with Type 2 Diabetes Mellitus at Increased Cardiovascular Risk in Greece.
Gourzoulidis G; Tzanetakos C; Ioannidis I; Tsapas A; Kourlaba G; Papageorgiou G; Maniadakis N
Clin Drug Investig; 2018 May; 38(5):417-426. PubMed ID: 29349708
[TBL] [Abstract][Full Text] [Related]
3. Cost-utility of empagliflozin in patients with type 2 diabetes at high cardiovascular risk.
Nguyen E; Coleman CI; Nair S; Weeda ER
J Diabetes Complications; 2018 Feb; 32(2):210-215. PubMed ID: 29157870
[TBL] [Abstract][Full Text] [Related]
4. Cost-effectiveness Analysis of Empagliflozin in Japan Based on Results From the Asian subpopulation in the EMPA-REG OUTCOME Trial.
Kaku K; Haneda M; Sakamaki H; Yasui A; Murata T; Ustyugova A; Chin R; Hirase T; Shibahara T; Hayashi N; Kansal A; Kaspers S; Okamura T
Clin Ther; 2019 Oct; 41(10):2021-2040.e11. PubMed ID: 31561882
[TBL] [Abstract][Full Text] [Related]
5. Cost-effectiveness of empagliflozin versus canagliflozin, dapagliflozin, or standard of care in patients with type 2 diabetes and established cardiovascular disease.
Reifsnider OS; Kansal AR; Gandhi PK; Cragin L; Brand SB; Pfarr E; Fahrbach K; Ustyugova A
BMJ Open Diabetes Res Care; 2021 May; 9(1):. PubMed ID: 33941549
[TBL] [Abstract][Full Text] [Related]
6. Economic modelling of costs associated with outcomes reported for type 2 diabetes mellitus (T2DM) patients in the CANVAS and EMPA-REG cardiovascular outcomes trials.
Kamstra R; Durkin M; Cai J; Bookhart B; Lafeuille MH; Pilon D; Tiggelaar S; Manceur AM; Lefebvre P
J Med Econ; 2019 Mar; 22(3):280-287. PubMed ID: 30575426
[TBL] [Abstract][Full Text] [Related]
7. Effects of empagliflozin on first and recurrent clinical events in patients with type 2 diabetes and atherosclerotic cardiovascular disease: a secondary analysis of the EMPA-REG OUTCOME trial.
McGuire DK; Zinman B; Inzucchi SE; Wanner C; Fitchett D; Anker SD; Pocock S; Kaspers S; George JT; von Eynatten M; Johansen OE; Jamal W; Mattheus M; Elsasser U; Hantel S; Lund SS
Lancet Diabetes Endocrinol; 2020 Dec; 8(12):949-959. PubMed ID: 33217335
[TBL] [Abstract][Full Text] [Related]
8. Cost-Effectiveness of Empagliflozin in Patients With Diabetic Kidney Disease in the United States: Findings Based on the EMPA-REG OUTCOME Trial.
Reifsnider OS; Kansal AR; Wanner C; Pfarr E; Koitka-Weber A; Brand SB; Stargardter M; Wang C; Kuti E; Ustyugova A
Am J Kidney Dis; 2022 Jun; 79(6):796-806. PubMed ID: 34752913
[TBL] [Abstract][Full Text] [Related]
9. Empagliflozin and Clinical Outcomes in Patients With Type 2 Diabetes Mellitus, Established Cardiovascular Disease, and Chronic Kidney Disease.
Wanner C; Lachin JM; Inzucchi SE; Fitchett D; Mattheus M; George J; Woerle HJ; Broedl UC; von Eynatten M; Zinman B;
Circulation; 2018 Jan; 137(2):119-129. PubMed ID: 28904068
[TBL] [Abstract][Full Text] [Related]
10. Empagliflozin and Cardiovascular and Kidney Outcomes across KDIGO Risk Categories:
Levin A; Perkovic V; Wheeler DC; Hantel S; George JT; von Eynatten M; Koitka-Weber A; Wanner C;
Clin J Am Soc Nephrol; 2020 Oct; 15(10):1433-1444. PubMed ID: 32994159
[TBL] [Abstract][Full Text] [Related]
11. Empagliflozin Reduced Mortality and Hospitalization for Heart Failure Across the Spectrum of Cardiovascular Risk in the EMPA-REG OUTCOME Trial.
Fitchett D; Inzucchi SE; Cannon CP; McGuire DK; Scirica BM; Johansen OE; Sambevski S; Kaspers S; Pfarr E; George JT; Zinman B
Circulation; 2019 Mar; 139(11):1384-1395. PubMed ID: 30586757
[TBL] [Abstract][Full Text] [Related]
12. Estimating the number of preventable cardiovascular disease events in the United States using the EMPA-REG OUTCOME trial results and National Health and Nutrition Examination Survey.
Wong ND; Fan W; Pak J
Diab Vasc Dis Res; 2020; 17(4):1479164120945674. PubMed ID: 32722930
[TBL] [Abstract][Full Text] [Related]
13. Empagliflozin reduces cardiovascular events, mortality and renal events in participants with type 2 diabetes after coronary artery bypass graft surgery: subanalysis of the EMPA-REG OUTCOME® randomised trial.
Verma S; Mazer CD; Fitchett D; Inzucchi SE; Pfarr E; George JT; Zinman B
Diabetologia; 2018 Aug; 61(8):1712-1723. PubMed ID: 29777264
[TBL] [Abstract][Full Text] [Related]
14. Cost-effectiveness of Empagliflozin Compared with Dapagliflozin for the Treatment of Patients with Type 2 Diabetes Mellitus and Established Cardiovascular Disease in Greece.
Gourzoulidis G; Tzanetakos C; Ioannidis I; Tsimihodimos V; Diogo V; Karpouzos G; Papageorgiou G; Kourlaba G
Clin Drug Investig; 2021 Apr; 41(4):371-380. PubMed ID: 33687695
[TBL] [Abstract][Full Text] [Related]
15. Effects of empagliflozin on the urinary albumin-to-creatinine ratio in patients with type 2 diabetes and established cardiovascular disease: an exploratory analysis from the EMPA-REG OUTCOME randomised, placebo-controlled trial.
Cherney DZI; Zinman B; Inzucchi SE; Koitka-Weber A; Mattheus M; von Eynatten M; Wanner C
Lancet Diabetes Endocrinol; 2017 Aug; 5(8):610-621. PubMed ID: 28666775
[TBL] [Abstract][Full Text] [Related]
16. Short-Term Changes in Albuminuria and Risk of Cardiovascular and Renal Outcomes in Type 2 Diabetes Mellitus: A Post Hoc Analysis of the EMPA-REG OUTCOME Trial.
Waijer SW; Xie D; Inzucchi SE; Zinman B; Koitka-Weber A; Mattheus M; von Eynatten M; Inker LA; Wanner C; Heerspink HJL
J Am Heart Assoc; 2020 Sep; 9(18):e016976. PubMed ID: 32893717
[TBL] [Abstract][Full Text] [Related]
17. Cost-effectiveness of empagliflozin as add-on to standard of care for chronic kidney disease management in the United Kingdom.
Ramos M; Gerlier L; Uster A; Muttram L; Frankel AH; Lamotte M
J Med Econ; 2024; 27(1):777-785. PubMed ID: 38758099
[TBL] [Abstract][Full Text] [Related]
18. Cost-effectiveness of empagliflozin compared with liraglutide based on cardiovascular outcome trials in Type II diabetes.
Ramos M; Ustyugova A; Hau N; Lamotte M
J Comp Eff Res; 2020 Aug; 9(11):781-794. PubMed ID: 32573253
[No Abstract] [Full Text] [Related]
19. Empagliflozin and kidney outcomes in Asian patients with type 2 diabetes and established cardiovascular disease: Results from the EMPA-REG OUTCOME
Kadowaki T; Nangaku M; Hantel S; Okamura T; von Eynatten M; Wanner C; Koitka-Weber A
J Diabetes Investig; 2019 May; 10(3):760-770. PubMed ID: 30412655
[TBL] [Abstract][Full Text] [Related]
20. Usefulness of Empagliflozin Versus Liraglutide for Prevention of Cardiovascular Mortality.
Arbel R; Hammerman A; Azuri J
Am J Cardiol; 2018 Sep; 122(6):981-984. PubMed ID: 30075890
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
